Kymera Therapeutics
Quarterly Financials
| Values in thousands | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
|---|---|---|---|---|
Revenue | $0 | $65,000 | $34,365 | $2,860 |
Gross Profit | 65,000 | 34,365 | 79,038 | |
EBITDA | -129,914 | -59,100 | -67,151 | -85,152 |
EBIT | -131,937 | -61,130 | -69,173 | -87,184 |
Net Income | -131,999 | -61,211 | -69,234 | -87,030 |
Net Change In Cash | 0 | 65,000 | 34,365 | 2,860 |
Free Cash Flow | -78,228 | -54,538 | -89,274 | -66,853 |
Cash | 373,374 | 124,477 | 144,090 | 357,011 |
Basic Shares | 100,097 | 98,177 | 97,534 | 84,390 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $39,200 | $47,072 | $78,592 | $46,826 |
Gross Profit | 39,200 | 47,072 | 78,592 | 46,826 |
EBITDA | -303,061 | -216,236 | -143,201 | -151,655 |
EBIT | -311,374 | -223,609 | -146,766 | -154,632 |
Net Income | -311,400 | -223,858 | -146,962 | -154,808 |
Net Change In Cash | 39,200 | 47,072 | 78,592 | 46,826 |
Cost of Revenue | 20,433 | |||
Free Cash Flow | -234,340 | -207,339 | -137,305 | -155,921 |
Cash | 357,011 | 120,256 | 109,966 | 68,395 |
Basic Shares | 84,390 | 75,043 | 58,365 | 53,933 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-09-30 | -$1.32 |
2026-06-30 | -$0.62 |
2026-03-31 | -$0.71 |
2025-12-31 | -$0.97 |